(0.80%) 5 277.51 points
(1.51%) 38 686 points
(-0.01%) 16 735 points
(-0.05%) $76.95
(4.29%) $2.70
(-0.18%) $2 341.50
(-0.23%) $30.37
(0.44%) $1 046.60
(0.01%) $0.921
(-0.01%) $10.48
(-0.05%) $0.785
(-0.36%) $90.10
Live Chart Being Loaded With Signals
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States...
Stats | |
---|---|
Today's Volume | 2.95M |
Average Volume | 1.40M |
Market Cap | 4.12B |
EPS | HKD0 ( 2024-03-26 ) |
Next earnings date | ( HKD0 ) 2024-08-19 |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -4.86 |
ATR14 | HKD0.0340 (0.48%) |
Volume Correlation
CARsgen Therapeutics Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CARsgen Therapeutics Correlation - Currency/Commodity
CARsgen Therapeutics Financials
Annual | 2023 |
Revenue: | HKD0 |
Gross Profit: | HKD0 (0.00 %) |
EPS: | HKD-1.340 |
FY | 2023 |
Revenue: | HKD0 |
Gross Profit: | HKD0 (0.00 %) |
EPS: | HKD-1.340 |
FY | 2022 |
Revenue: | HKD0 |
Gross Profit: | HKD0 (0.00 %) |
EPS: | HKD-1.620 |
FY | 2021 |
Revenue: | HKD25.81M |
Gross Profit: | HKD25.81M (100.00 %) |
EPS: | HKD-8.36 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
CARsgen Therapeutics
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators